PRMT1通过甲基化SRSF1缓解异上腺素诱导的心肌缩
Zi Yan1,2, Wenhui Zhao1, Naixin Zhao1
1Department of Physiology, Shanxi Medical University, Taiyuan 030001, China.
Acta biochimica et biophysica Sinica
|December 11, 2024
概括
蛋白质氨酸甲基转移酶1 (PRMT1) 通过甲基化氨酸/氨酸丰富的拼接因子1 (SRSF1) 来改善心肌缩 (MH). 这一发现为MH机制和心血管疾病的潜在治疗点提供了新的见解.
科学领域:
- 心血管生物学 心血管生物学
- 疾病的分子机制.
- 表观遗传学和基因调控
背景情况:
- 心肌缩 (MH) 是严重心血管疾病的重要危险因素.
- 蛋白质氨酸甲基转移酶1 (PRMT1) 影响MH的确切机制尚未完全理解.
- 富含氨酸/氨酸的拼接因子1 (SRSF1) 通过替代拼接在心血管疾病进展中起作用.
研究的目的:
- 研究PRMT1在MH的背景下调节SRSF1中的作用.
- 阐明PRMT1对SRSF1和MH的影响的分子机制.
- 探索针对PRMT1-SRSF1轴的MH潜在治疗策略.
主要方法:
- 在成年雄性小鼠和H9C2心肌细胞中建立异上腺素 (ISO) 诱导的MH模型.
- 在MH模型中分析PRMT1和SRSF1表达水平.
- 研究PRMT1和SRSF1之间的相互作用,包括甲基化和酸化.
- 评估SRSF1对CaMKIIδ拼接变体的影响以及对MH的后续影响.
主要成果:
- 在ISO诱导的MH中,PRMT1的表达减少,其抑制会加剧MH,而过度表达会改善它.
- 在MH中SRSF1是上调的,并作为PRMT1.1的下游目标.
- SRSF1调节CaMKIIδ剪接,影响着MH的发育.
- PRMT1直接与SRSF1相互作用,通过甲基化减少其酸化,从而改善MH.
结论:
- 通过甲基化和调节SRSF1活动,PRMT1对MH具有保护作用.
- PRMT1-SRSF1通路代表了 MH 病变发生的一个新机制.
- 针对PRMT1-SRSF1相互作用可能为管理MH和相关心血管疾病提供新的治疗方法.
更多相关视频
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
1.1K
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
6.1K
相关概念视频
01:31Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385